Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference41 articles.
1. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation;Suda;Cancer Metastasis Rev.,2010
2. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?;Gazdar;Trends Mol. Med.,2004
3. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib;Pao;PLoS Med.,2005
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
5. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials;Schuler;Lung Cancer (Amsterdam, Netherlands),2019